| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803022202036 | 302220203 | VORICONAZOLE/TEVA F.C.TAB 200MG/TAB BTx14 (PVC/Al blister) | 160.78 | 168.66 | 203.81 |
| 05/2018 | 2803022202135 | 302220213 | VORICONAZOLE/TEVA F.C.TAB 200MG/TAB BTx14x1 (PVC/Al blister) | 160.78 | 168.66 | 203.81 |
For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp.
Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.
The minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.
The oral bioavailability is estimated to be 96% (CV 13%).
Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.
* 4.6 L/kg